In this study, we demonstrate that genetic deletion or pharmacological inhibition of IP6K1 in hepatocytes upregulates apoA-I, a major structural and functional protein of HDL, augmenting cholesterol efflux, and attenuating atherosclerosis. The gene discussed is IP6K1; the disease is atherosclerosis.